Navigation Links
CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
Date:9/10/2012

KING OF PRUSSIA, Pa., Sept. 10, 2012 /PRNewswire/ -- CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The Company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.

"We are very pleased to again be working with the U.S. Government on its pandemic preparedness efforts," said Dr. John Anderson, Senior Vice President of CSL Biotherapies.  "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."

Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract No HHSO100201200011I.  The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract.

About CSL Biotherapies

The United States headquarters of CSL Biotherapies are located in King of Prussia, PA. Its parent company, CSL Limited, in Melbourne, Australia (ASX: CSL) has invested  US$ 80million to double the Company's influenza manufacturing capacity to 40 million trivalent influenza vaccine doses per season, making it one of the largest influenza vaccine facilities for global markets. CSL Biotherapies, which shares its United States headquarters with its sister company, CSL Behring, commercializes influenza vaccine products globally. The CSL Group employs more than 11,000 people and operates in 27 countries worldwide. For more information, visit us at www.csl.com.au and at http://www.cslbiotherapies-us.com.

Media Contact:  
Sheila Burke
Director, Commercial Operations Communications and Public Relations
610-878-4209


'/>"/>
SOURCE CSL Biotherapies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. K computer research results awarded ACM Gordon Bell Prize
2. BioPower Systems Awarded $5 Million from Victorian Government
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
5. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
6. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
7. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
8. Sloan Research Fellowships Awarded to 126 Young Scholars
9. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
10. Chemring Detection Systems Awarded $500k for Strategic Research and Development
11. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/8/2016)... 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... finalists for clean technology companies in the TSX Venture 50 ... companies listed on the TSX Venture Exchange, in each of ... clean technology & life sciences, diversified industries and technology ... to return on investment, market cap growth, trading volume and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas ... is the Executive Vice President for Corporate Services and the Chief Financial Officer ... Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply Chain, and Investments. , ...
(Date:2/8/2016)... , Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the ... Eugene Seymour , MD, MPH, will present information about the ... Waldorf-Astoria Hotel in New York City . ... in the Windsor Room at 5:30PM EST. Registered attendees can request ... New York City . --> New ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
Breaking Biology News(10 mins):